Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC
Executive Summary
Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.
You may also be interested in...
Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Asia Deal Watch: FujiFilm, Hisun Team To Develop Flu Drug For Chinese Market
Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.